Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.verified

XERS

Price:

$1.93

Market Cap:

$286.13M

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its pr...[Read more]

Industry

Biotechnology

IPO Date

2018-06-21

Stock Exchange

NASDAQ

Ticker

XERS

The PE Ratio as of May 2024 (TTM) for Xeris Biopharma Holdings, Inc. (XERS) is -4.11

According to Xeris Biopharma Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.11. This represents a change of -17.06% compared to the average of -4.96 of the last 4 quarters.

Xeris Biopharma Holdings, Inc. (XERS) Historical PE Ratio (quarterly & annually)

How has XERS PE Ratio performed in the past?

The mean historical PE Ratio of Xeris Biopharma Holdings, Inc. over the last ten years is -2.63. The current -4.11 PE Ratio has changed 15.52% with respect to the historical average. Over the past ten years (40 quarters), XERS's PE Ratio was at its highest in in the March 2020 quarter at -0.55. The PE Ratio was at its lowest in in the September 2018 quarter at -6.07.

Quarterly (TTM)
Annual

Average

-2.63

Median

-2.23

Minimum

-5.20

Maximum

-1.54

Xeris Biopharma Holdings, Inc. (XERS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Xeris Biopharma Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 172.72%

Maximum Annual PE Ratio = -1.54

Minimum Annual Increase = -45.24%

Minimum Annual PE Ratio = -5.20

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.20172.72%
2022-1.91-22.10%
2021-2.4543.09%
2020-1.71-15.36%
2019-2.02-40.74%
2018-3.41120.70%
2017-1.54-45.24%

Xeris Biopharma Holdings, Inc. (XERS) Average PE Ratio

How has XERS PE Ratio performed in the past?

The current PE Ratio of Xeris Biopharma Holdings, Inc. (XERS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-3.18

5-year avg

-2.66

10-year avg

-2.63

Xeris Biopharma Holdings, Inc. (XERS) PE Ratio vs. Peers

How is XERS’s PE Ratio compared to its peers?

Xeris Biopharma Holdings, Inc.’s PE Ratio is less than Protalix BioTherapeutics, Inc. (13.12), less than Seres Therapeutics, Inc. (-1.62), less than Cidara Therapeutics, Inc. (-1.50), greater than ImmunityBio, Inc. (-7.30), less than Galera Therapeutics, Inc. (-0.23), greater than Mereo BioPharma Group plc (-58.75), greater than Terns Pharmaceuticals, Inc. (-4.90), less than PDS Biotechnology Corporation (-2.44), less than Inozyme Pharma, Inc. (-3.66), less than HOOKIPA Pharma Inc. (-2.11), less than X4 Pharmaceuticals, Inc. (-1.40), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than eFFECTOR Therapeutics, Inc. (-0.21), greater than Elevation Oncology, Inc. (-4.62), less than Hepion Pharmaceuticals, Inc. (-0.15),

Build a custom stock screener for Xeris Biopharma Holdings, Inc. (XERS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xeris Biopharma Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xeris Biopharma Holdings, Inc. (XERS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xeris Biopharma Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Xeris Biopharma Holdings, Inc.'s PE Ratio?

How is the PE Ratio calculated for Xeris Biopharma Holdings, Inc. (XERS)?

What is the highest PE Ratio for Xeris Biopharma Holdings, Inc. (XERS)?

What is the 3-year average PE Ratio for Xeris Biopharma Holdings, Inc. (XERS)?

What is the 5-year average PE Ratio for Xeris Biopharma Holdings, Inc. (XERS)?

How does the current PE Ratio for Xeris Biopharma Holdings, Inc. (XERS) compare to its historical average?